Cyclo Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:CYTH

0.68

0.00 (-0.29%)

6:53:43 PM EDT: $0.69 +0.01 (+1.46%)

Market Cap (Intraday)	19.46M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.29 Million
Adjusted EPS	-$0.16

See more estimates

10-Day MA	$0.78
50-Day MA	$1.11
200-Day MA	$1.39

See more pivots

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CYTH

6714 NW 16th Street, Suite B, Gainesville, Florida 32653

United States of America

Phone: +1.386.418.8060

Number of Employees: 8

http://www.cyclotherapeutics.com

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.